The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2005Testing of small molecules in an alpha-synuclein pre-clinical model of Parkinson’s disease
Although Parkinson’s disease is mainly sporadic, at least six genes have been recently linked to familial PD. It is believed that a molecular understanding of the consequences of these gene mutations...
-
Target Validation, 2005In vivo Target Validation: RNA Interference to Silence Alpha-Synuclein in Parkinson’s Disease Pre-clinical Models
Recent studies have shown that a protein known as alpha-synuclein plays a central role in the development of Parkinson’s disease. While its normal function in the brain remains unknown, the...
-
Target Validation, 2005Metabotropic glutamate receptors in L-DOPA-induced dyskinesia
Levodopa-induced dyskinesia in Parkinson’s disease is thought to depend on an overactive stimulation of brain glutamate receptors. This project aims to evaluate a particular class of glutamate...
-
Target Validation, 2005Discovery of Allosteric Potentiators of mGluR7 as Novel Antiparkinsonian Agents
Exciting advances over recent years have identified specific pathways in the brain that become overactive in patients with Parkinson’s disease. The primary pathology of Parkinson’s disease involves...
-
Target Validation, 2005Validating Toxic Protein Aggregation as a Therapeutic Target in PD (2)
The aggregation/fibrillation of the presynaptic protein alpha-synuclein is a key factor in the development of Parkinson’s disease. There is a critical need for an effective treatment of Parkinson’s...
-
Target Validation, 2005Screening of Small Molecule Libraries to Identify Trace Amine Receptor Ligands Active in Treatment of PD
For the treatment of Parkinson’s disease, no direct dopamine agonist compares in efficacy to levodopa, suggesting that levodopa itself or its metabolites may affect targets in addition to dopamine...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.